664 related articles for article (PubMed ID: 8267489)
1. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
[TBL] [Abstract][Full Text] [Related]
2. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
Arch Intern Med; 1997 Dec 8-22; 157(22):2562-8. PubMed ID: 9531224
[TBL] [Abstract][Full Text] [Related]
3. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
4. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.
Elliott CG; Hiltunen SJ; Suchyta M; Hull RD; Raskob GE; Pineo GF; Jensen RL; Yeates S; Kitterman N
Arch Intern Med; 1994 May; 154(9):999-1004. PubMed ID: 8179457
[TBL] [Abstract][Full Text] [Related]
5. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
Vandiver JW; Vondracek TG
Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
[TBL] [Abstract][Full Text] [Related]
6. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
Anand S; Ginsberg JS; Kearon C; Gent M; Hirsh J
Arch Intern Med; 1996 Aug 12-26; 156(15):1677-81. PubMed ID: 8694666
[TBL] [Abstract][Full Text] [Related]
7. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
Kitchen S; Preston FE
Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
[TBL] [Abstract][Full Text] [Related]
9. Monitoring heparin anticoagulation in the acute phase response.
Uprichard J; Manning RA; Laffan MA
Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
[TBL] [Abstract][Full Text] [Related]
10. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
11. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
[TBL] [Abstract][Full Text] [Related]
12. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
Baker BA; Adelman MD; Smith PA; Osborn JC
Arch Intern Med; 1997 Nov; 157(21):2475-9. PubMed ID: 9385299
[TBL] [Abstract][Full Text] [Related]
13. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
Vandiver JW; Vondracek TG
Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
[TBL] [Abstract][Full Text] [Related]
14. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
Hull RD; Pineo GF
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
[TBL] [Abstract][Full Text] [Related]
15. A standard heparin nomogram for the management of heparin therapy.
Cruickshank MK; Levine MN; Hirsh J; Roberts R; Siguenza M
Arch Intern Med; 1991 Feb; 151(2):333-7. PubMed ID: 1789820
[TBL] [Abstract][Full Text] [Related]
16. Optimal therapeutic level of heparin therapy in patients with venous thrombosis.
Hull RD; Raskob GE; Rosenbloom D; Lemaire J; Pineo GF; Baylis B; Ginsberg JS; Panju AA; Brill-Edwards P; Brant R
Arch Intern Med; 1992 Aug; 152(8):1589-95. PubMed ID: 1497392
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; van den Berg-Segers AE; Cariou R; Leeuwenkamp O; Lensing AW;
N Engl J Med; 2003 Oct; 349(18):1695-702. PubMed ID: 14585937
[TBL] [Abstract][Full Text] [Related]
18. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
[TBL] [Abstract][Full Text] [Related]
19. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
Ao PY; Hawthorne WJ; Coombs R; Fletcher JP
Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369
[TBL] [Abstract][Full Text] [Related]
20. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]